Genomic analyses have revealed that HRAS mutations occur in 6% of HNSCC at initial diagnosis [41] and in 15% of patients during acquisition of resistance to cetuximab [42], and HRAS mutations have been demonstrated to correlate with reduced response of HNSCC patients to cetuximab treatment [43]. This evidence concerns the gene HRAS and head and neck squamous cell carcinoma.